How does Helicobacter pylori infection interact with non-steroidal anti-inflammatory drugs?

There have been conflicting clinical data on whether Helicobacter pylori (H. pylori) contributes to the pathogenesis of ulcers induced by non-steroidal anti-inflammatory drugs (NSAIDs). The discrepant findings reflect the complex interaction between H. pylori and NSAIDs, which has generated divergent results under different clinical conditions. This chapter reviews the pathogenetic mechanisms in ulcer formation that are common to H. pylori and NSAIDs, and explains how a better understanding of these factors might resolve some of the controversies. Existing evidence indicates that the interaction between H. pylori and NSAIDs is not an 'all-or-none' relationship. Factors such as previous exposure to NSAIDs, a past history of ulcer complication, gastric acid output, neutrophil infiltration, concurrent acid suppressive therapy and the type of NSAID used (aspirin versus non-aspirin NSAIDs) would influence the role of H. pylori as a risk factor in NSAID users. Recommendations on H. pylori eradication for different subgroups of NSAID users are proposed.

[1]  M. Rué,et al.  Helicobacter pylori infection is a protective factor for bleeding gastric ulcers but not for bleeding duodenal ulcers in NSAID users , 2000, Alimentary pharmacology & therapeutics.

[2]  K. McColl,et al.  Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole , 1999, Gut.

[3]  C. Hawkey,et al.  Neutrophils, Helicobacter pylori, and nonsteroidal anti-inflammatory drug ulcers. , 1999, Gastroenterology.

[4]  A. Groen,et al.  Gallbladder bile patients with ileal Crohn's disease is markedly enriched in bile pigments and calcium , 1999 .

[5]  F. Chan,et al.  Helicobacter pylori eradication in long-term users of non-steroidal anti-inflammatory drugs , 1998, The Lancet.

[6]  Lau,et al.  Does eradication of Helicobacter pylori impair healing of nonsteroidal anti‐inflammatory drug associated bleeding peptic ulcers? A prospective randomized study , 1998, Alimentary pharmacology & therapeutics.

[7]  Á. Lanas,et al.  Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study , 1998, The Lancet.

[8]  W. Leung,et al.  Eradication of H. Pylori versus maintenance acid suppression to prevent recurrent ulcer hemorrhage in high risk NSAID users: A prospective randomizd study , 1998 .

[9]  W. Leung,et al.  Expression of cyclooxygenase 1 (Cox-1) and 2 (Cox-2) in H. Pylori associated gastritis , 1998 .

[10]  A. Barkun,et al.  Omeprazole Compared with Misoprostol for Ulcers Associated with Nonsteroidal Antiinflammatory Drugs , 1998 .

[11]  C. Hawkey,et al.  A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. , 1998, The New England journal of medicine.

[12]  J. Stachura,et al.  Infection of Helicobacter pylori in gastric adaptation to continued administration of aspirin in humans. , 1998, Gastroenterology.

[13]  F. Chan,et al.  Helicobacter pylori, NSAIDs, and peptic ulcers , 1998, The Lancet.

[14]  F. Chan,et al.  Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers , 1997, The Lancet.

[15]  W. Rees,et al.  The influence of age, gender, Helicobacter pylori and smoking on gastric mucosal adaptation to non‐steroidal anti‐inflammatory drugs , 1997, Alimentary pharmacology & therapeutics.

[16]  J. Wallace Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. , 1997, Gastroenterology.

[17]  R. Russell,et al.  Association of antral mucosal levels of interleukin 8 and reactive oxygen radicals in patients infected with Helicobacter pylori. , 1997, Clinical science.

[18]  P. Unge,et al.  Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. , 1996, Scandinavian journal of gastroenterology.

[19]  G. Porro,et al.  Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy. , 1996, Gut.

[20]  S. L. Elliott,et al.  INDOMETHACIN DAMAGE TO RAT GASTRIC MUCOSA IS MARKEDLY DEPENDENT ON LUMINAL pH , 1996, Clinical and experimental pharmacology & physiology.

[21]  A. Blum,et al.  Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. , 1996, Gastroenterology.

[22]  E. Fontham,et al.  Antral atrophy, Helicobacter pylori colonization, and gastric pH. , 1996, American journal of clinical pathology.

[23]  E. Hui,et al.  Helicobacter pylori infection increases the risk of peptic ulcers in chronic users of non-steroidal anti-inflammatory drugs. , 1996, Scandinavian journal of rheumatology.

[24]  J. Wallace,et al.  Indomethacin-induced gastric injury and leukocyte adherence in arthritic versus healthy rats. , 1995, Gastroenterology.

[25]  E. El-Omar,et al.  A substantial proportion of non-ulcer dyspepsia patients have the same abnormality of acid secretion as duodenal ulcer patients. , 1995, Gut.

[26]  L. Laine,et al.  Interaction of NSAIDs and Helicobacter pylori on gastrointestinal injury and prostaglandin production: a controlled double‐blind trial , 1995, Alimentary pharmacology & therapeutics.

[27]  W. Ray,et al.  Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. , 1995, American journal of epidemiology.

[28]  R. Russell,et al.  Mucosal erosions in longterm non-steroidal anti-inflammatory drug users: predisposition to ulceration and relation to Helicobacter pylori. , 1995, Gut.

[29]  J. Konturek,et al.  Mucosal adaptation to aspirin induced gastric damage in humans. Studies on blood flow, gastric mucosal growth, and neutrophil activation. , 1994, Gut.

[30]  J. Jenner,et al.  Increased gastric juice epidermal growth factor after non-steroidal anti-inflammatory drug ingestion. , 1994, Gut.

[31]  P. O’Brien,et al.  Effect of nonsteroidal anti-inflammatory drugs on LFA-1 and ICAM-1 expression in gastric mucosa. , 1994, The American journal of physiology.

[32]  D. Graham,et al.  Helicobacter pylori infection and development of gastric or duodenal ulcer in arthritic patients receiving chronic NSAID therapy. The Misoprostol Study Group. , 1994, The American journal of gastroenterology.

[33]  J. Primrose,et al.  Interleukin-8 expression in Helicobacter pylori infected, normal, and neoplastic gastroduodenal mucosa. , 1994, Journal of clinical pathology.

[34]  C. Corbishley,et al.  Prevalence of Helicobacter pylori infection and its effect on symptoms and non-steroidal anti-inflammatory drug induced gastrointestinal damage in patients with rheumatoid arthritis. , 1993, Gut.

[35]  C. Hawkey,et al.  Effect of Helicobacter pylori colonisation on gastric mucosal eicosanoid synthesis in patients taking non-steroidal anti-inflammatory drugs. , 1993, Gut.

[36]  I. Nakshabendi,et al.  Gastric and duodenal mucosal blood flow in patients receiving non‐steroidal anti‐inflammatory drugs—influence of age, smoking, ulceration and Helicobacter pylori , 1993, Alimentary pharmacology & therapeutics.

[37]  M. Feldman,et al.  Aspirin-induced acute gastric mucosal injury is a neutrophil-dependent process in rats. , 1992, The American journal of physiology.

[38]  D. Heresbach,et al.  Helicobacter pylori: a risk and severity factor of non-steroidal anti-inflammatory drug induced gastropathy. , 1992, Gut.

[39]  W. Karnes,et al.  Helicobacter pylori secretes a chemotactic factor for monocytes and neutrophils. , 1992, Gut.

[40]  J. Wallace,et al.  Modulation of leukocyte adhesion in rat mesenteric venules by aspirin and salicylate. , 1992, Gastroenterology.

[41]  A. Zinsmeister,et al.  Long-term nonsteroidal anti-inflammatory drug use and gastroduodenal injury: the role of Helicobacter pylori. , 1992, Gastroenterology.

[42]  R. Coffey,et al.  Increased production of transforming growth factor alpha following acute gastric injury. , 1992, Gastroenterology.

[43]  I. Nakshabendi,et al.  Chemical gastritis and Helicobacter pylori related gastritis in patients receiving non-steroidal anti-inflammatory drugs: comparison and correlation with peptic ulceration. , 1992, Journal of clinical pathology.

[44]  R. Levine,et al.  Nonsalicylate nonsteroidal antiinflammatory drugs augment prestimulated acid secretion in rabbit parietal cells. Investigation of the mechanisms of action. , 1991, Gastroenterology.

[45]  J. Wallace,et al.  Role of oxygen-derived free radicals in indomethacin-induced gastric injury. , 1991, The American journal of physiology.

[46]  D. Graham,et al.  Long-term nonsteroidal antiinflammatory drug use and Helicobacter pylori infection. , 1991, Gastroenterology.

[47]  D. Graham,et al.  Effect of Helicobacter pylori infection on the severity of gastroduodenal mucosal injury after the acute administration of naproxen or aspirin to normal volunteers. , 1991, The American journal of gastroenterology.

[48]  K. Takeuchi,et al.  Effect of indomethacin on gastric mucosal blood flow around acetic acid-induced gastric ulcers in rats. , 1991, Gastroenterology.

[49]  W. Ray,et al.  Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. , 1991, Annals of internal medicine.

[50]  D. M. Jones,et al.  Serological evidence of infection with Helicobacter pylori may predict gastrointestinal intolerance to non-steroidal anti-inflammatory drug (NSAID) treatment in rheumatoid arthritis. , 1991, British journal of rheumatology.

[51]  B. Rathbone,et al.  Helicobacter pylori associated chronic gastritis and peptic ulceration in patients taking non‐steroidal anti‐inflammatory drugs , 1990, Alimentary pharmacology & therapeutics.

[52]  J. Wallace,et al.  Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process. , 1990, The American journal of physiology.

[53]  J. Wallace,et al.  The mucoid cap over superficial gastric damage in the rat: A high-pH microenvironment dissipated by nonsteroidal antiinflammatory drugs and endothelin , 1990 .

[54]  M. Baggiolini,et al.  Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. , 1989, The Journal of clinical investigation.

[55]  M. Hochberg,et al.  The presence of Campylobacter pylori in nonsteroidal antiinflammatory drug associated gastritis. , 1989, The Journal of rheumatology.

[56]  E. Montgomery,et al.  Campylobacter pylori, NSAIDS, and smoking: risk factors for peptic ulcer disease. , 1989, The American journal of gastroenterology.

[57]  J. Van Damme,et al.  Human granulocyte chemotactic peptide (IL-8) as a specific neutrophil degranulator: comparison with other monokines. , 1989, Immunology.

[58]  G. Stabellini,et al.  Campylobacter-like organisms, nonsteroidal anti-inflammatory drugs and gastric lesions in patients with rheumatoid arthritis. , 1989, Digestion.

[59]  D. Graham,et al.  Gastric adaptation: Studies in humans during continuous aspirin administration , 1988 .

[60]  R. Russell,et al.  Campylobacter pylori associated gastritis in patients with rheumatoid arthritis taking nonsteroidal anti-inflammatory drugs. , 1988, British journal of rheumatology.

[61]  J. Koo,et al.  Gastric Mucosal Blood Flow in Misoprostol Pretreated Aspirin‐induced Ulceration , 1988, Annals of surgery.

[62]  A. Slomiany,et al.  Evidence for weakening of gastric mucus integrity by Campylobacter pylori. , 1988, Scandinavian journal of gastroenterology.

[63]  P. Guth,et al.  Effect of aspirin plus hydrochloric acid on the gastric mucosal microcirculation. , 1987, Gastroenterology.

[64]  J. Redfern,et al.  Effect of indomethacin on gastric mucosal prostaglandins in humans. Correlation with mucosal damage. , 1987, Gastroenterology.

[65]  A. Slomiany,et al.  Effect of acetylsalicylic acid on gastric mucin viscosity, permeability to hydrogen ion, and susceptibility to pepsin. , 1986, Biochemical pharmacology.

[66]  S. Ashley,et al.  Focal gastric mucosal blood flow at the site of aspirin-induced ulceration. , 1985, American journal of surgery.

[67]  M. Feldman,et al.  Effect of indomethacin on gastric acid and bicarbonate secretion in humans , 1984 .

[68]  M. Ligumsky,et al.  Aspirin can inhibit gastric mucosal cyclo-oxygenase without causing lesions in rat , 1983 .

[69]  J. Barrowman,et al.  Endoscopic diagnosis of intestinal metaplasia in Canada and Japan. , 1981, Journal of clinical gastroenterology.

[70]  M. Whitehouse,et al.  Biochemical gastroprotection from acute ulceration induced by aspirin and related drugs. , 1980, Biochemical pharmacology.

[71]  J. K. van der Korst,et al.  Hypochlorhydria and hypergastrinaemia in rheumatoid arthritis. , 1979, Annals of the rheumatic diseases.

[72]  C. Flexner,et al.  Effect of indomethacin and aspirin on gastric blood flow and acid secretion. , 1977, The Journal of pharmacology and experimental therapeutics.

[73]  W. Ritchie,et al.  Influence of isoproterenol and cholestyramine on acute gastric mucosal ulcerogenesis. , 1977, Gastroenterology.

[74]  E. Hinchey,et al.  Effect of gastric acidity on gastric ulceration induced by hemorrhage in the rat, utilizing a gastric chamber technique. , 1973, Gastroenterology.